Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis
Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is rep...
Gespeichert in:
Veröffentlicht in: | Fundamental & clinical pharmacology 2022-04, Vol.36 (2), p.286-295 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 295 |
---|---|
container_issue | 2 |
container_start_page | 286 |
container_title | Fundamental & clinical pharmacology |
container_volume | 36 |
creator | Al‐Kadi, Alaa El‐Daly, Mahmoud El‐Tahawy, Nashwa F. G. Khalifa, Mohamed Montaser A. Ahmed, Al‐Shaimaa F. |
description | Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient. |
doi_str_mv | 10.1111/fcp.12718 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2555347075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638248019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EokNhwQsgS2zoYlpf4kuW1YgWpEqwgLXlOMcdD4kd7GSqeQ8eGE-nsEDCmyNL3__pHP0IvaXkktZ35d10SZmi-hla0UaxtWZEPkcroqRa81bTM_SqlB0hVBEqX6Iz3nDSEtmu0K_reB_SDLGEiO3QpzJDThFwiNvQhTnlgsM45bQHXJa8D3s7YBt7bEcYQsp2Bvwj9BEONbFb8nH0i4MedwdcYCqh4Hmb03K_rflpylBKSBEnX0E_2HG08_H_qJzSNKeaeI1eeDsUePM0z9H3m4_fNp_Wd19uP2-u79aOC66Pl3HWkk6Ttm-IpKIjjIhGKCs1c0wILaRTvfPgtW2IoIxocIxZL4V30PBz9OHkrff9XKDMZgzFwTDYCGkppioEbxRRoqLv_0F3acmxbmeY5Jo1mtC2UhcnyuVUSgZvphxGmw-GEnOsytSqzGNVlX33ZFy6Efq_5J9uKnB1Ah7CAIf_m8zN5utJ-RvJ-qBP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638248019</pqid></control><display><type>article</type><title>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Al‐Kadi, Alaa ; El‐Daly, Mahmoud ; El‐Tahawy, Nashwa F. G. ; Khalifa, Mohamed Montaser A. ; Ahmed, Al‐Shaimaa F.</creator><creatorcontrib>Al‐Kadi, Alaa ; El‐Daly, Mahmoud ; El‐Tahawy, Nashwa F. G. ; Khalifa, Mohamed Montaser A. ; Ahmed, Al‐Shaimaa F.</creatorcontrib><description>Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/fcp.12718</identifier><identifier>PMID: 34309069</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aldosterone ; Aldosterone - pharmacology ; Aldosterone - therapeutic use ; Angiotensin ; Angiotensins - pharmacology ; Angiotensins - therapeutic use ; angiotensin‐II ; Animals ; Apoptosis ; Caspase ; Cecum ; CLP ; Design of experiments ; Disease Models, Animal ; Experimental design ; Hospitals ; Humans ; IL‐6 ; Immunosuppression ; Inflammation ; Inflammation - drug therapy ; Inflammation - pathology ; Inhibitors ; Intensive care units ; Kidney ; Kidneys ; losartan ; Oxidative stress ; Parameters ; Pharmacology ; ramipril ; Rats ; Renal function ; Renin ; Sepsis ; Sepsis - complications ; Sepsis - drug therapy ; spironolactone ; Survival ; TNF‐α</subject><ispartof>Fundamental & clinical pharmacology, 2022-04, Vol.36 (2), p.286-295</ispartof><rights>2021 Société Française de Pharmacologie et de Thérapeutique</rights><rights>2021 Société Française de Pharmacologie et de Thérapeutique.</rights><rights>2022 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</citedby><cites>FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</cites><orcidid>0000-0001-5971-1104 ; 0000-0001-9875-6399</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffcp.12718$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffcp.12718$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34309069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al‐Kadi, Alaa</creatorcontrib><creatorcontrib>El‐Daly, Mahmoud</creatorcontrib><creatorcontrib>El‐Tahawy, Nashwa F. G.</creatorcontrib><creatorcontrib>Khalifa, Mohamed Montaser A.</creatorcontrib><creatorcontrib>Ahmed, Al‐Shaimaa F.</creatorcontrib><title>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.</description><subject>Aldosterone</subject><subject>Aldosterone - pharmacology</subject><subject>Aldosterone - therapeutic use</subject><subject>Angiotensin</subject><subject>Angiotensins - pharmacology</subject><subject>Angiotensins - therapeutic use</subject><subject>angiotensin‐II</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Caspase</subject><subject>Cecum</subject><subject>CLP</subject><subject>Design of experiments</subject><subject>Disease Models, Animal</subject><subject>Experimental design</subject><subject>Hospitals</subject><subject>Humans</subject><subject>IL‐6</subject><subject>Immunosuppression</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - pathology</subject><subject>Inhibitors</subject><subject>Intensive care units</subject><subject>Kidney</subject><subject>Kidneys</subject><subject>losartan</subject><subject>Oxidative stress</subject><subject>Parameters</subject><subject>Pharmacology</subject><subject>ramipril</subject><subject>Rats</subject><subject>Renal function</subject><subject>Renin</subject><subject>Sepsis</subject><subject>Sepsis - complications</subject><subject>Sepsis - drug therapy</subject><subject>spironolactone</subject><subject>Survival</subject><subject>TNF‐α</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi0EokNhwQsgS2zoYlpf4kuW1YgWpEqwgLXlOMcdD4kd7GSqeQ8eGE-nsEDCmyNL3__pHP0IvaXkktZ35d10SZmi-hla0UaxtWZEPkcroqRa81bTM_SqlB0hVBEqX6Iz3nDSEtmu0K_reB_SDLGEiO3QpzJDThFwiNvQhTnlgsM45bQHXJa8D3s7YBt7bEcYQsp2Bvwj9BEONbFb8nH0i4MedwdcYCqh4Hmb03K_rflpylBKSBEnX0E_2HG08_H_qJzSNKeaeI1eeDsUePM0z9H3m4_fNp_Wd19uP2-u79aOC66Pl3HWkk6Ttm-IpKIjjIhGKCs1c0wILaRTvfPgtW2IoIxocIxZL4V30PBz9OHkrff9XKDMZgzFwTDYCGkppioEbxRRoqLv_0F3acmxbmeY5Jo1mtC2UhcnyuVUSgZvphxGmw-GEnOsytSqzGNVlX33ZFy6Efq_5J9uKnB1Ah7CAIf_m8zN5utJ-RvJ-qBP</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Al‐Kadi, Alaa</creator><creator>El‐Daly, Mahmoud</creator><creator>El‐Tahawy, Nashwa F. G.</creator><creator>Khalifa, Mohamed Montaser A.</creator><creator>Ahmed, Al‐Shaimaa F.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5971-1104</orcidid><orcidid>https://orcid.org/0000-0001-9875-6399</orcidid></search><sort><creationdate>202204</creationdate><title>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</title><author>Al‐Kadi, Alaa ; El‐Daly, Mahmoud ; El‐Tahawy, Nashwa F. G. ; Khalifa, Mohamed Montaser A. ; Ahmed, Al‐Shaimaa F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-3983290b809d40615b0205457a682c255856c7dcfef8a4051208ec22af65fce43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aldosterone</topic><topic>Aldosterone - pharmacology</topic><topic>Aldosterone - therapeutic use</topic><topic>Angiotensin</topic><topic>Angiotensins - pharmacology</topic><topic>Angiotensins - therapeutic use</topic><topic>angiotensin‐II</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Caspase</topic><topic>Cecum</topic><topic>CLP</topic><topic>Design of experiments</topic><topic>Disease Models, Animal</topic><topic>Experimental design</topic><topic>Hospitals</topic><topic>Humans</topic><topic>IL‐6</topic><topic>Immunosuppression</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - pathology</topic><topic>Inhibitors</topic><topic>Intensive care units</topic><topic>Kidney</topic><topic>Kidneys</topic><topic>losartan</topic><topic>Oxidative stress</topic><topic>Parameters</topic><topic>Pharmacology</topic><topic>ramipril</topic><topic>Rats</topic><topic>Renal function</topic><topic>Renin</topic><topic>Sepsis</topic><topic>Sepsis - complications</topic><topic>Sepsis - drug therapy</topic><topic>spironolactone</topic><topic>Survival</topic><topic>TNF‐α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al‐Kadi, Alaa</creatorcontrib><creatorcontrib>El‐Daly, Mahmoud</creatorcontrib><creatorcontrib>El‐Tahawy, Nashwa F. G.</creatorcontrib><creatorcontrib>Khalifa, Mohamed Montaser A.</creatorcontrib><creatorcontrib>Ahmed, Al‐Shaimaa F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al‐Kadi, Alaa</au><au>El‐Daly, Mahmoud</au><au>El‐Tahawy, Nashwa F. G.</au><au>Khalifa, Mohamed Montaser A.</au><au>Ahmed, Al‐Shaimaa F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2022-04</date><risdate>2022</risdate><volume>36</volume><issue>2</issue><spage>286</spage><epage>295</epage><pages>286-295</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract>Sepsis is an extensive life‐threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis‐induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP‐nontreated and CLP‐treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty‐four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase‐3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone‐treated and 60% in losartan‐treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34309069</pmid><doi>10.1111/fcp.12718</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5971-1104</orcidid><orcidid>https://orcid.org/0000-0001-9875-6399</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0767-3981 |
ispartof | Fundamental & clinical pharmacology, 2022-04, Vol.36 (2), p.286-295 |
issn | 0767-3981 1472-8206 |
language | eng |
recordid | cdi_proquest_miscellaneous_2555347075 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Aldosterone Aldosterone - pharmacology Aldosterone - therapeutic use Angiotensin Angiotensins - pharmacology Angiotensins - therapeutic use angiotensin‐II Animals Apoptosis Caspase Cecum CLP Design of experiments Disease Models, Animal Experimental design Hospitals Humans IL‐6 Immunosuppression Inflammation Inflammation - drug therapy Inflammation - pathology Inhibitors Intensive care units Kidney Kidneys losartan Oxidative stress Parameters Pharmacology ramipril Rats Renal function Renin Sepsis Sepsis - complications Sepsis - drug therapy spironolactone Survival TNF‐α |
title | Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T10%3A02%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20aldosterone%20inhibitors%20improve%20survival%20and%20ameliorate%20kidney%20injury%20induced%20by%20sepsis%20through%20suppression%20of%20inflammation%20and%20apoptosis&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Al%E2%80%90Kadi,%20Alaa&rft.date=2022-04&rft.volume=36&rft.issue=2&rft.spage=286&rft.epage=295&rft.pages=286-295&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/10.1111/fcp.12718&rft_dat=%3Cproquest_cross%3E2638248019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638248019&rft_id=info:pmid/34309069&rfr_iscdi=true |